RNA Formulation Videos
-
Scale Up And Manufacturing Of RNA-LNPs For A COVID-19 Vaccine
4/13/2022
Dr. Jason Coleman, Clinical Application Scientist Lead with Precision NanoSystems, presents on an overview of the development and scale-up activities needed to progress this saRNA vaccine to the clinic.
-
Insights And Strategies For GMP Manufacturing Of RNA-Lipid Nanoparticles
4/25/2024
The emergence of RNA-encapsulated-lipid nanoparticles has introduced a seismic shift in biopharma innovation. But how will the industry adapt to diversifying applications and scales going forward?
-
Transforming Nanoparticle Formulations From Bench To Commercial Scale
11/11/2025
Unlock seamless transition from lab-scale nanoparticle research to commercial production. Learn how scalable turbulent-jet mixing ensures precise, uniform, and reproducible formulation results.
-
The Next Frontier In mRNA: Modular Manufacturing For Scalable RNA-LNP Therapies
1/29/2025
Explore constructing a modular RNA-LNP GMP facility using Cytiva's FlexFactory™ process train in a KUBio™ environment to scale RNA-LNP therapies.
-
In What Ways Are We Underestimating LNP Complexity Today?
12/4/2024
As the RNA-LNP space continues to diversify beyond linear mRNA and infectious disease vaccines, Kate Zhang of Hopewell Therapeutics, Sumit Luthra of Sanofi, and Ben Muir of BioNTech each address several misconceptions about LNP composition today and how the rise of novel RNA modalities, more advanced mechanisms of action, and novel lipids are challenging our understanding of/work with LNPs today.
-
The mRNA Journey: From Design To LNP-Ready Molecules For Research
11/25/2025
Learn a validated, end-to-end protocol for producing high-quality in vitro transcription (IVT) mRNA for preclinical research. Find out how to optimize sequence design, small-scale synthesis, and more.
-
Five Practical Considerations To Move From Concept To Clinic
12/17/2025
Learn more about five key factors for advancing targeted in vivo LNP programs, from formulation and targeting strategies to bioanalytical readiness and scalability.
-
Accelerate Your pDNA And mRNA Process Development
11/13/2025
Explore a structured approach to optimizing and scaling plasmid DNA production using E. coli, with insights into key growth parameters, benchtop feasibility, and pilot-scale performance.
-
Q&A On Formulation & Stability Of LNPs
11/28/2022
Russell Johnson, VP Formulation Research for RVAC Medicines, and Aalok Shah, Director of Formulation & Drug Delivery, Strand Therapeutics, address audience questions around the importance of drug substance and drug product stability in efficient delivery in this segment of the Bioprocess Online Live! event LNPs & Beyond: Opportunities in RNA Delivery.
-
The NanoAssemblr® Spark™ Robust Low Volume RNA-Lipid Nanoparticle Formulation
4/14/2022
Develop RNA-lipid nanoparticles (LNPs) in under 10 seconds for drug discovery and early preclinical development. The NanoAssemblr®️ Spark™ instrument enables rapid µL formulations to conserve limited and expensive ingredients with minimal waste.